Skip to main content
Signal8

Retension Pharmaceuticals, Inc. Form 8-K — Nov 18, 2026

Form 8-KItems 2.02, 9.01Filed Nov 18, 2026, 8:10 AM ET0001104659-26-129354Original filing

Retension Pharmaceuticals reported a Q3 2026 net loss of $5.9 million (EPS -$7.33), widened from $1.5 million a year ago, driven by Phase 2b clinical trial costs as R&D spend rose to $5.0 million from $1.4 million. The clinical-stage biotech has no revenue. The company completed an upsized IPO in October 2026, selling 4,312,500 shares at $12.00 per share for $51.75 million in gross proceeds and roughly $45.1 million net. Pro forma cash stands at approximately $54.3 million, funding the ongoing Phase 2b trial of lead candidate RTN-001 in about 280 patients with uncontrolled hypertension.

Key figures

Cash Position
9190083
Ipo shares
4312500
Total assets
14148496
Greenshoe shares
562500
Ipo net proceeds
45100000
Phase2b patients
280
Total liabilities
6658829
Ipo gross proceeds
51750000
Q3 2025 ga expense
299574
Q3 2025 rd expense
1365256
Q3 2026 ga expense
990759
Q3 2026 rd expense
5016602
Ipo price per share
12
Pro forma cash incl ipo
54300000
Rtm 001 subjects studied
265

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.